Otros idiomas Oryzon Genomics S.A.

Acciones

ORY

ES0167733015

Mercado cerrado - BME Otros sitios de cotización 17:35:02 22/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,962 ^EUR	-2,39 %		-3,35 %	+3,92 %

07/05	EN DIRECTO DESDE LOS MERCADOS: Zalando, Banco de Sabadell, Sacyr, Amadeus IT, UniCredit, Rémy Cointeau, UBS, Infineon, Palantir, BBVA...
06/05	Oryzon Genomics S.A. comunica los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Oryzon Genomics S A : to provide corporate progress updates at several events in May	09/05
Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Oryzon Genomics S A : reports financial results and corporate update for quarter ended March 31, 2024	06/05
IN DIRETTA DAI MERCATI: Netweek, Ence Energia, Enel, OVS, Sogefi, Telecom Italia, ASML, Novartis, Airbus, Apple, Nvidia, Boeing...	23/04
Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	22/04
Oryzon Genomics S A : secures another important patent for its lead CNS asset, vafidemstat	22/04
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	08/04
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	08/04
Oryzon Genomics S A : to provide corporate progress updates at several events in April	05/04
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023	26/02
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26/02
ORYZON to Provide Corporate Progress Updates at Several Events in February-March	05/02
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024	19/01
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)	05/01
Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder	05/01
ORYZON to Provide Corporate Progress Updates at Several Events in January	03/01
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.	04/12
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million	21/11
Oryzon Genomics S.A. announced that it expects to receive ?45 million in funding from Nice & Green SA	21/11
Oryzon Completes Patient Testing in Mid-stage Study of Borderline Personality Disorder Drug	07/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Oryzon Genomics S.A.

Acciones

ORY

ES0167733015

Otros idiomas

Filtros